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Abstract
Objective:  Retinopathy  of  prematurity  (ROP),  the  leading  cause  of  childhood  blindness  around
the world,  is  potentially  avoidable.  The  incidence  of  ROP  varies  between  countries  due  to  a
variety of  factors.  The  aim  of  this  study  is  to  assess  the  effectiveness  of  screening  criteria  in
Mexico valid  in  March  2015  as  an  example  of  a  middle-income  country.
Methods:  The  medical  records  of  261  patients  from  a  single  center  covering  a  period  of
42 months  (October  2011--March  2015)  were  retrospectively  analyzed  to  identify  infants  with
ROP that  did  not  fall  within  screening  criteria  set  forth  by  regional  health  authorities.
Results: Of  the  261  infants  in  our  study  group,  55  (21.1%)  weighed  more  than  1500  g  (ranging
from 466  to  2910),  129  (49.4%)  had  a  GA  >30  weeks  (ranging  from  22  to  36),  and  47  (18%)  patients
presented  both.  Overall,  the  mean  birth  weight  for  infants  with  ROP  was  1270.6  ±  365.3  g.
The mean  gestational  age  was  30.4  ±  2.3  weeks.  Following  actual  AAO/AAP  guidelines  for  ROP
screening,  17  infants  (6.5%)  in  our  study  group  would  have  gone  undiagnosed.
Conclusions:  These  ﬁndings  show  that  the  valid  guidelines  at  the  time  of  the  screening  were
based on  a  different  population  and  were  not  sufﬁcient  to  detect  all  ROP  cases  in  a  middle-
income country.  With  the  update  of  the  Mexican  guidelines  established  in  July  2015,  the  patients
from this  study  would  have  been  screened.  Therefore,  review  and  modiﬁcation  of  the  current∗ Corresponding autor at: Retina Service, Asociación para Evitar la Ceguera Hospital ‘‘Luis Sánchez Bulnes’’ I.A.P., Vicente Garcia Torres
No. 46 Coyoacán, 04030 México, D.F., Mexico. Tel.: +52 5510841400x1171.
E-mail address: mamc@dr.com (M.A. Martínez-Castellanos).
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screening  guidelines  in  other  middle-income  countries  should  be  considered  to  include  all  babies
at risk  for  ROP.
©  2016  Sociedad  Mexicana  de  Oftalmolog´ıa.  Published  by  Masson  Doyma  Me´xico  S.A.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Evidencia  para  modiﬁcar  las  guías  de  tamizaje  de  retinopatía  del  prematuro
para  prevenir  ceguera  infantil  en  países  emergentes
Resumen
Objetivo:  La  retinopatía  del  prematuro  (ROP),  la  principal  causa  de  ceguera  infantil  del  mundo,
es potencialmente  prevenible.  La  incidencia  de  ROP  varía  entre  países  debido  a  múltiples  fac-
tores. El  propósito  de  este  estudio  es  analizar  la  efectividad  de  las  guías  de  tamizaje  vigentes
en México  durante  marzo  de  2015  como  país  en  vías  de  desarrollo.
Métodos:  Los  expedientes  de  261  pacientes  de  un  único  centro,  cubriendo  un  periodo  de
42 meses  (octubre  2011--marzo  2015),  fueron  analizados  identiﬁcando  pacientes  con  ROP  que
no entraban  en  los  criterios  de  tamizaje  establecidos  por  las  autoridades  de  salud.
Resultados:  De  los  261  lactantes  del  estudio,  55  pacientes  (21.1%)  pesaron  más  de  1,500  g
(intervalo  de  466--2910),  129  (49.4%)  tuvieron  una  edad  gestacional  mayor  a  30  semanas  al
nacer (intervalo  de  22--36)  y  47  (18%)  presentaron  ambos.  El  peso  promedio  de  los  pacientes
con ROP  fue  de  1,270  ±  365.3  g.  La  edad  gestacional  al  nacimiento  fue  de  30.4  ±  2.3  semanas.
Siguiendo las  guías  de  tamizaje  de  la  AAO/AAP,  17  pacientes  (6.5%)  del  estudio  no  hubieran  sido
diagnosticados.
Conclusiones:  Estos  hallazgos  demuestran  que  las  guías  de  tamizaje  vigentes  en  México  durante
el estudio  estaban  basadas  en  una  población  diferente  y  no  eran  suﬁcientes  para  detectar  todos
los casos  de  ROP.  Con  la  actualización  de  las  guías  mexicanas  en  julio  2015,  esta  población  sí
hubiera estado  cubierta,  por  lo  que  la  revisión  y  modiﬁcación  de  estas  guías  en  otros  países
emergentes  debe  ser  considerada  para  incluir  a  todos  los  bebés  en  riesgo  de  presentar  ROP.
© 2016  Sociedad  Mexicana  de  Oftalmolog´ıa.  Publicado  por  Masson  Doyma  Me´xico  S.A.  Este  es
un art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licencias/
by-nc-nd/4.0/).
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etinopathy  of  prematurity  (ROP)  is  a  serious  condition
ound  in  newborns  and  is  characterized  by  abnormal  vas-
ular  growth  in  the  immature  retina.  This  abnormal  vessel
evelopment  can  lead  to  blindness  in  severe  cases.  It  is  now
idely  recognized  that  ROP  is  the  leading  cause  of  child-
ood  blindness.1 As  neonatal  mortality  around  the  world
ecreases,  ROP  is  no  longer  seen  only  in  the  most  developed
ountries.  Developing  countries  are  now  seeing  a  spike  in
OP  prevalence  often  referred  to  as  the  ‘‘third  epidemic,’’
ue  to  the  higher  premature  birth  rates,  decreased  access
o  neonatal  resources,  and  possibly  due  to  lack  of  awareness
r  training  of  healthcare  professionals.2,3 Of  the  estimated
0,000  children  to  have  ROP,  over  half  are  located  within
atin  America.1,2,4 The  main  risk  factors  for  developing  ROP
re  inherent  to  premature  infants,  namely  gestational  age
GA)  and  birth  weight  (BW).1,5 Both  of  these  have  been
ccepted  as  the  two  most  important  risk  factors  for  devel-
ping  ROP.  However,  continued  monitoring  has  helped  us  to
nderstand  that  other  risk  factors  play  an  important  role
n  ROP  development  including  artiﬁcial  ventilation,  sep-
is,  necrotizing  enterocolitis,  postnatal  glucocorticoids,  and
ardiopathy.6--8
s
d
a
gDue  to  the  subclinical  nature  of  ROP,  the  diagnosis  can
e  missed  during  the  initial  hospital  stay.  This  can  be  detri-
ental  to  the  child  mainly  because  early  detection  and
reatment  is  vital  to  avoid  blindness  in  serious  cases.  As
uch,  screening  guidelines  have  been  put  into  place  across
he  globe  to  help  detect  and  treat  this  disease  early.  This
s  especially  relevant  to  middle-income  countries  as  the
ate  of  premature  infant  survival  is  rapidly  improving,  fol-
owed  closely  by  an  increase  in  ROP  prevalence.1,2,9 Mexico,
 middle-income  country,  has  witnessed  this  increase  ﬁrst
and.  Even  with  national  screening  guidelines,  ROP  con-
inues  to  be  the  leading  cause  of  childhood  blindness  in
exico.4,10 The  criteria  that  most  institutions  in  Mexico  rec-
gnize  and  follow  was  released  by  the  American  Academy
f  Pediatrics  and  the  American  Academy  of  Ophthalmology
n  1990  and  revised  in  1995,  2008  and  2013.11 These  guide-
ines  state  that  any  infant  of  GA  of  less  than  30  weeks  or
ith  BW  of  less  than  1500  g  should  be  screened.  The  2013
evision  also  included  select  infants  with  BW  1500  g  and  GA
reater  than  30  weeks  with  an  unstable  clinical  course  that
hould  be  screened.  This  includes  infants  who  are  on  car-
iorespiratory  support  or  at  high  risk  for  developing  ROP
ccording  to  the  neonatologist.11 However,  the  use  of  these
uidelines  is  meant  for  developed  countries  with  excellent
mat
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DEvidence  to  modify  guidelines  for  routine  retinopathy  of  pre
prenatal  care.5 Because  of  the  vast  diversity  in  neonatal
care  around  the  world,  the  AAO/AAP  guidelines  may  not  be
applicable  to  middle  income  countries.2--5,9,12--14 Mexico,  a
middle  income  country,  does  not  have  the  same  facilities
or  neonatal  care  to  allow  adequate  implementation  of  the
AAO/AAP  guidelines.  The  Mexican  Secretary  of  Health  (SSA
--  Spanish  acronym)  released  its  own  guidelines  in  2010  that
followed  the  2008  AAO/AAP  recommendations  closely.10 As
such,  healthcare  workers  mainly  follow  the  guidelines  put
into  place  by  the  AAO/AAP,  the  only  difference  being  that
they  recommend  screening  babies  of  GA  ≤  32  weeks  instead
of  30  weeks.  In  the  Clinical  Practice  Guidelines  released
by  the  SSA,  an  unstable  clinical  course  is  deﬁned  as  the
need  to  use  vasopressor  drugs  or  mechanical  ventilation  to
keep  the  vital  signs  within  the  normal  range.  Babies  born
outside  of  these  criteria  may  develop  ROP  and  not  receive
much  needed  treatment.  Therefore,  in  July  2015,  The  SSA
released  an  update  in  the  screening  guidelines  in  which  they
established  that  all  babies  born  of  GA  ≤  34  weeks  or  less
that  1750  g,  with  oxygen  exposure  or  with  any  associated
risk  factor  should  be  screened.  Institutions  in  middle-income
countries  should  be  aware  of  additional  screening  criteria
that  would  allow  identiﬁcation  of  all  ROP  patients  in  need
of  care.
The  purpose  of  this  study  is  to  report  the  incidence  of
ROP  in  infants  who  do  not  fall  within  the  AAP/AAO  retinopa-
thy  of  prematurity  screening  criteria  in  order  to  better  help
identify  infants  at  risk  for  ROP  in  Mexico  and  other  middle-
income  countries.
Methods
This  study  was  authorized  by  the  IRB  and  Research  Com-
mittee  of  the  Asociación  para  Evitar  la  Ceguera  en  México
‘‘Dr.  Luis  Sánchez  Bulnes’’  I.A.P.  (APEC).  A  retrospective
study  was  performed  by  analyzing  patient’s  charts  that  were
screened  for  ROP  between  the  dates  of  October  2011  and
March  2015.  Patients  who  were  included  were  all  from  the
APEC,  a  tertiary  care  hospital  of  ophthalmology.  Records
of  prenatal  and  postnatal  care  are  included  in  this  study.
Patients  were  grouped  based  on  GA,  BW,  and  stage  of  ROP  for
analysis.  The  study  mainly  focused  on  infants  that  were  out-
liers  to  the  general  screening  guidelines  (GA  >  30,  BW  >  1500)
in  which  a  diagnosis  of  ROP  was  made.
Patients  were  generally  screened  between  4  and  6  weeks
of  age  and  were  followed  until  complete  vasculariza-
tion  of  the  retina  was  achieved.  The  child’s  demographic
information  was  documented  including  BW,  GA,  medical
history  and  any  previous  interventions.  Systematic  risk  fac-
tors  that  could  be  associated  with  ROP  development  were
also  recorded  including  sepsis,  cardiopulmonary  support,
respiratory  distress  syndrome,  hyaline  membrane  disease,
intraventricular  hemorrhage  (IVH),  necrotizing  entero-
colitis,  pneumonia,  surfactant  treatment,  transfusions,
glucocorticoid  administration,  cardiopathy,  or  supplemental
oxygen  use.
Diagnosis  of  ROP  was  performed  by  ophthalmologists
according  to  the  International  Classiﬁcation  of  Retinopa-
thy  of  Prematurity  and  described  according  to  grade  and
stage.15 ROP  was  subsequently  treated  using  antiangiogenic
therapy  with  a  single  dose  of  Bevacizumab  or  Ranibizumab  if
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eeded.16,17 For  cases  of  ROP  that  did  not  regress  or  were  too
dvanced  for  antiangiogenic  treatment,  laser  therapy  or  vit-
ectomy  was  performed.  Indications  for  treatment  followed
he  guidelines  of  ETROP.18
Data  was  collected  and  compiled  according  to  GA,  BW
nd  ROP  diagnosis.  Special  attention  was  given  to  infants
eighing  more  than  1500  g  at  birth  or  with  GA  greater  than
0  weeks  as  determined  by  a  neonatologist.
esults
rom  October  2011  to  March  2015,  268  patients  were
creened  for  ROP.  of  these  patients,  7  (2.61%)  were  not
ncluded  in  the  study  due  to  incomplete  follow-up  or  miss-
ng  data.  The  data  from  261  individuals  (97.39%)  who  were
ncluded  in  the  study  was  collected  and  compiled  for  exam-
nation.  For  all  individuals  in  the  study,  the  mean  GA  was
0.2  ±  2.34  weeks  while  the  mean  BW  was  1270.6  ±  365.68  g.
f  the  261  infants  screened,  216  (82.76%)  were  diagnosed
ith  ROP  in  either  eye,  with  71  (32.87%)  of  those  patients
equiring  treatment.  The  study  included  patients  ranging
rom  22  to  36  weeks  GA  and  466  to  2932  g  BW.  Tables  1  and  2
escribe  the  demographic  data  of  all  patients  screened  for
OP.
Of  the  216  patients  diagnosed  with  ROP,  200  (92.59%)
f  them  had  bilateral  ROP  involvement.  Staging  ROP  is  the
est  indicator  as  to  the  severity  of  the  disease.  Among  the
22  eyes,  416  eyes  were  diagnosed  with  ROP:  118  (28.37%)
ere  stage  1,  165  (39.66%)  were  stage  2,  36  (8.65%)  were
tage  3,  45  (10.82%)  were  stage  4,  and  52  (12.5%)  were
tage  5.  Table  3  shows  the  stages  of  ROP  along  with  their
espective  mean  BW  and  GA.
Other  risk  factors  for  the  development  of  ROP  outside  of
A  and  BW  are  vast.  Many  other  studies  have  shown  a  corre-
ation  between  ROP  and  a  variety  of  comorbidities.  Some  of
he  most  notable  comorbidities  noted  in  our  study  included
epsis,  interventricular  hemorrhage  of  all  grades,  necrotiz-
ng  enterocolitis,  pneumonia,  respiratory  distress  syndrome,
yaline  membrane  disease,  bronchopulmonary  dysplasia,
urfactant  usage,  corticosteroid  usage,  and  transfusions.7,19
n  this  study,  240  (92%)  infants  diagnosed  with  ROP  suffered
ith  at  least  one  comorbidity.
Using  the  current  AAO/AAP  screening  guidelines  (screen
nfants  BW  ≤  1500  g  or  GA  ≤  30  weeks),10 47  infants  (94  eyes)
n  our  study  group  fell  outside  of  the  screening  criteria  and
ould  not  have  been  screened.  Of  these  94  eyes,  56  (59.6%)
ad  any  grade  of  ROP  while  23  (24.5%)  eyes  went  on  to
evelop  threshold  ROP,  with  9  (9.6%)  of  them  requiring  treat-
ent.  Even  with  the  new  qualiﬁcation  included  in  the  2013
evision  of  AAO/AAP  guidelines  (screen  infants  1500--2000  g
r  >30  weeks  with  an  unstable  clinical  course),  the  criteria
ould  still  exclude  58  eyes  (29  infants)  from  the  screening.
f  these  58  eyes,  34  eyes  (58.6%)  were  diagnosed  with  any
tage  of  ROP,  17  (29.3%)  of  which  developed  stage  3  ROP  or
orse  with  5  (8.6%)  of  them  requiring  treatment.
iscussionhis  study  retrospectively  reviews  the  diagnosis  and  treat-
ent  of  216  infants  diagnosed  with  ROP  over  the  course  of  42
onths.  Our  main  purpose  was  to  analyze  the  effectiveness
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Table  1  Demographic  data  presenting  birth  weight  in  relation  to  ROP  diagnosis.
≤1500  g  1501--1999  g  ≥2000  g
Total  eyes 412  92  18
With ROP  diagnosis  346  56  14
With treatment  104  15  3
Stages
1 92  22  4
No treatment
76
Treatment
16a
No  treatment
21
Treatment
1a
No  treatment
4
Treatment
0
2 148  15  2
No treatment
120
Treatment
28a
No  treatment
10
Treatment
5a
No  treatment
1
Treatment
1a
3  34  2  0
No treatment
0
Treatment
34
No  treatment
0
Treatment
2
No  treatment
0
Treatment
0
4 34  10  1
No treatment
14
Treatment
20
No  treatment
4
Treatment
6
No  treatment
1
Treatment
0
5 38  7  7
No treatment
32
Treatment
6
No  treatment
6
Treatment
1
No  treatment
5
Treatment
2
Of the 110 eyes belonging to the 55 infants with BW >1500 g, 70 were diagnosed with ROP: 26 (37.1%) eyes were diagnosed with stage 1
ROP, 17 (24.3%) eyes with stage 2, 2 (2.9%) with stage 3, 11 (15.7%) with stage 4, and 14 (20%) with stage 5. Of the 70 eyes, 18 required
treatment.
a These patients were treated at an external hospital and had already regressed to the stated stage by the time of our ﬁrst follow-up
visit.
Table  2  Demographic  data  presenting  gestational  age  at  birth  in  relation  to  ROP  diagnosis.
≤30  weeks  30.1--33.9  weeks  ≥34  weeks
Total  eyes  263  218  40
With ROP  diagnosis  238  153  25
With treatment  82  35  5
Stages
1 54  55  9
No treatment
42
Treatment
12a
No  treatment
50
Treatment
5a
No  treatment
9
Treatment
0
2 118  41  6
No treatment
87
Treatment
31a
No  treatment
38
Treatment
3a
No  treatment
6
Treatment
0
3 19  16  1
No treatment
0
Treatment
19
No  treatment
0
Treatment
16
No  treatment
0
Treatment
1
4 24  15  6
No treatment
8
Treatment
16
No  treatment
8
Treatment
7
No  treatment
3
Treatment
3
5 23  26  3
No treatment
19
Treatment
4
No  treatment
22
Treatment
4
No  treatment
2
Treatment
1
Of the 258 eyes belonging to the 129 infants with GA >30 weeks, 178 were diagnosed with ROP: 64 eyes (36%) were diagnosed with stage
1, 47 eyes (26.4%) with stage 2, 17 eyes (9.6%) with stage 3, 21 eyes (11.8%) with stage 4, and 29 eyes (16.3%) with stage 5. Of the 178
eyes with ROP, 40 required treatment.
a These patients were treated at an external hospital and had already regressed to the stated stage by the time of our ﬁrst follow-up
visit.
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Table  3  Stages  of  ROP  along  with  their  respective  mean  BW  and  GA.
Stage  1  2  3  4  5
Number  of  eyes 118  165  36  45  52
Mean BW  (g)  346.25  1119.67  1139.33  1235.27  1400.87
Mean ±  SD  333.19  301.51  256.37  403.43  406.41
Range (g)  694--2910  466--2400  466--1730  690--2100  800--2390
Mean GA  (weeks)  30.8  29.64  29.79  29.89  1400.87
Mean ±  SD  2.18  2.07  2.35  2.99  406.41
Range (weeks)  26--36  24--35  25--34  22--34  800--2390
Number of  eyes  treated  17a 34a 36  26  9
a These patients were treated at an external hospital and had already regressed to the stated stage by the time of our ﬁrst follow-up
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of  the  AAO/AAP  screening  guidelines  for  our  population  in
a  middle-income  country.  Our  data  shows  that  in  our  pop-
ulation,  diagnosis  of  ROP  is  not  uncommon  in  infants  who
fall  outside  the  AAO/AAP  ROP  screening  guidelines,  namely
those  with  birth  weight  >1500  g  and/or  gestational  age  >30
weeks.
As  noted  in  various  other  articles,  the  screening  crite-
ria  used  in  more  developed  nations  may  not  be  applicable
for  middle-income  countries.2--5,9,12--14 In  India,  reports  show
that  the  incidence  of  infants  >1500  g  treated  for  thresh-
old  ROP  with  cryotherapy  was  15.3%.20 A  study  in  Vietnam
reports  that  out  of  the  21  babies  with  threshold  ROP,  13  were
>1250  g  at  birth.21 In  Lithuania,  54%  of  the  infants  needing
treatment  for  ROP  were  >1500  g  at  birth.22 These  ﬁndings
were  not  similar  to  those  in  more  developed  countries.  Var-
ious  studies  in  the  United  States  indicate  that  threshold
disease  is  not  found  above  30  weeks  GA  or  >1500  g  BW23,24
which  is  deﬁnitely  not  the  case  with  our  population.  One
study  done  in  the  United  States  in  1996  did  indicate  the
presence  of  ROP  in  infants  with  BW  >  2000  g  when  suffering
hemorrhagic  shock  after  birth.25
Risk  factors  other  than  birth  weight  or  gestational  age
may  contribute  to  the  prevalence  of  ROP  amongst  heavier
and  older  babies.  There  are  many  systemic  illnesses  that  can
contribute  to  the  development  of  ROP  regardless  of  age,  but
especially  applicable  for  infants  who  are  not  included  in  the
general  screening  criteria  based  on  BW  and  GA.  They  include
sepsis,  pneumonia,  respiratory  distress,  hyaline  membrane
disease,  and  cardiac  abnormalities.7,19 Medical  interventions
also  play  a  role  in  developing  ROP.  As  shown  by  Wagner,
infants  who  were  treated  with  supplemental  oxygen  or  the
administration  of  CPAP  had  a  higher  rate  of  occurrence  for
ROP.26 Transfusions  during  the  neonate  period  also  increase
drastically  the  risk  of  developing  threshold  ROP.27 Surfactant
therapy,  while  extremely  beneﬁcial  for  premature  lungs,  has
been  shown  to  be  an  independent  risk  factor  for  developing
ROP.28
The  2013  revision  of  the  AAO/AAP  ROP  guidelines  state
that  infants  with  BW  1500--2000  g  or  with  GA  >  30  weeks  with
a  severe  clinical  course  should  be  screened  under  the  discre-
11tion  of  the  attending  neonatologists. Of  the  261  individuals
screened  in  our  study,  55  (21.1%)  weighed  more  than  1500  g
and  129  (49.4%)  had  a  GA  >30  weeks.  Furthermore,  47  (18%)
infants  had  both  GA  >30  weeks  and  BW  >1500  g,  29  of  which
b
w
t
rad  a  stable  clinical  course  which  would  have  left  them
ut  of  the  screening  criteria.  If  these  infants  had  not  been
creened,  17  patients  would  have  gone  undiagnosed  and  5
ould  have  been  left  untreated.  The  surprising  statistics  in
ur  study  was  the  prevalence  of  grade  3  or  higher  ROP  in
eavier  and  more  mature  infants.
Previous  studies  in  Mexico  performed  in  2005  and
008  have  shown  a  prevalence  of  ROP  to  be  around
4--28%  amongst  newborns,  with  about  10--11%  requir-
ng  treatment.29--31 These  studies  increased  their  screening
riteria  to  include  babies  with  GA  of  <32  weeks.  Our  study
ontained  infants  with  ROP  up  to  36  weeks  GA  and  up  to
910  g  BW.  At  the  time  of  our  study,  the  valid  screening
uidelines  were  the  Clinical  Practice  Guidelines  released
y  the  Mexican  Secretary  of  Health  in  2010  (screen  infants
W  ≤  1500  g,  GA  ≤  32  weeks,  or  GA  >  32  weeks  with  an  unsta-
le  clinical  course).  Following  these  criteria,  12  infants  (24
yes)  in  our  study  group  would  have  not  gone  through  the
creening  and  9  patients  would  have  gone  undiagnosed.  Of
hese  24  eyes,  18  had  any  grade  of  ROP  while  13  went  on
o  develop  threshold  ROP,  with  4  of  them  requiring  treat-
ent.  Using  the  current  guidelines  released  in  July  2015,
hese  patients  would  have  been  screened  and  appropriately
reated.  This  shows  that  in  our  population,  older  and  heavier
abies  are  at  risk  for  developing  ROP,  with  or  without  the
resence  of  associated  risk  factors.
In  our  population,  almost  all  children  with  ROP  had
ither  a GA  of  ≤34  weeks  or  a  BW  of  ≤1750  g.  Only  one
hild  (0.003%)  in  our  study  fell  outside  of  this  increased
creening  criteria  who  developed  stage  1  zone  III  ROP  in
oth  eyes  which  did  not  require  treatment  and  regressed
pontaneously.  With  this  increased  criteria  established  in  the
linical  Practice  Guidelines  of  July  2015  of  either  GA  ≤  34
eeks  or  BW  ≤  1750  g,  we  would  effectively  screen  the  pedi-
tric  population  at  risk  in  Mexico.
The  limitations  of  this  study  include  its  retrospective
ature,  the  urban  location  of  participating  hospitals,  and
ariable  duration  of  follow-up  visits.  Also,  as  a  tertiary  care
enter,  all  patients  were  referrals  for  ROP  screening  and
one  were  born  in  house.  Also,  some  infants  were  treated
efore  arriving  at  our  facility.  As  such,  there  were  some  that
ere  not  treated  in  accordance  to  our  standards,  mainly
hose  treated  for  stage  1  or  stage  2  ROP.  Further  studies  are
ecommended  to  analyze  the  prevalence  and  characteristics
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272  
f  ROP  in  a  more  rural  setting  and  to  assess  the  efﬁcacy  and
ost  of  the  proposed  increase  in  screening.
In  conclusion,  ROP  diagnosis  among  infants  weighing
1500  g  at  birth  and/or  with  gestational  age  of  >30  is  not
ncommon  in  Mexico  and  other  middle-income  countries.  As
his  study  shows,  the  current  screening  guidelines,  including
hose  recommended  by  AAO/AAP  are  not  completely  appli-
able  due  to  the  exclusion  of  some  patients  who  go  on  to
evelop  severe  ROP.  With  the  criteria  established  by  the  SSA
n  the  Clinical  Practice  Guidelines  of  July  2015,  we  would
ffectively  screen  the  pediatric  population  at  risk  in  Mexico.
eview  and  modiﬁcation  of  the  current  screening  guidelines
n  other  middle-income  countries  should  be  considered  in
rder  to  include  all  babies  at  risk  for  ROP.  Our  recommenda-
ions  include  increasing  the  screening  criteria  to  incorporate
ewborns  with  GA  ≤  34  weeks  or  BW  ≤  1750  g  regardless  of
ny  other  diagnosis.
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